HI HB17 | 2022 | Regular Session

Hawaii House Bill 17 (Prior Session Legislation)

Note: Carry Over of previous HB17

Status

Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on January 21 2021 - 25% progression, died in committee
Action: 2021-12-10 - Carried over to 2022 Regular Session.
Pending: House Health, Human Services, & Homelessness Committee
Text: Latest bill text (Introduced) [HTML]

Summary

Requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a sixteen per cent or more price increase over a twoyear period. Requires the drug manufacturer to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost increases by a certain amount during a specified time frame.

Title

Relating To Prescription Drugs.

History

Date	Chamber	Action
2021-12-10		Carried over to 2022 Regular Session.
2021-01-27	House	Referred to HHH, CPC, FIN, referral sheet 1
2021-01-21	House	Introduced and Pass First Reading.
2021-01-20	House	Pending introduction.

Same As/Similar To

SB605 (Same As) 2021-12-10 - Carried over to 2022 Regular Session.
HB17 (Carry Over) 2021-01-27 - Referred to HHH, CPC, FIN, referral sheet 1

Subjects

Department of Commerce and Consumer Affairs
Insurance Commissioner
Notification
Prescription Drugs
Price Increases

Hawaii State Sources

Type	Source
Summary	https://www.capitol.hawaii.gov/measure_indiv.aspx?billtype=HB&billnumber=17&year=2022
Text	https://www.capitol.hawaii.gov/session2022/bills/HB17_.HTM